Acyclic acetal derivatives of the selective antiherpesvirus agent 9-(3-hydroxypropoxy) guanine (BRL44385) and of its 2-aminopurine congener (BRL46720) have been prepared and evaluated in mice for oral delivery of BRLh4385. Guanine derivatives (6 a-c) were prepared~. Mitsunobu condensation of an alcohol with a 9-hydroxy-6-methoxypurine . Synthesis of derivatives of 2-aminopurine (tOa-d) was achieved by hydrogenolysis of 9-alkoxy-6-chloropurines, which were obtained either by reaction of an alkoxyamine with 4,6-dichloro-2,5-diformamidopyrimidine and subsequent ring closure or by Mitsunobu condensation of an alcohol with a 6-chloro-9-hydroxypurine. Following oral administration, 2-amino-9-[3-(isopropoxymethyl)propoxy]-purine (tob, BRL 55792) was very well absorbed and provided high and prolonged concentrations of BRL44385 in the blood. In a cutaneous HSV-1 infection in the ear pinna of mice, orally dosed BRL55792 was at least 3-fold more potent than both BRL44385 and Acyclovir in reduction of lesion severity.
Introduction 9-(3-Hydroxypropoxy)guanine (BRL44385) (Fig. 1) , . a novel nucleoside analogue in which an acyclic substituent is attached to N-9 of the purine via a nitrogen-oxygen bond, is a potent and selective inhibitor of the replication of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), varicella zoster virus (VZV) and Epstein-Barr virus (EBV) (Harnden et el., 1988a (Harnden et el., , 1988b (Harnden et el., , 1990 . However, like other acyclic analogues of guanosine it is only poorly absorbed after oral administration to animals ). 2-Aminopurine, 2,6-diaminopurine and 2-amino-6-alkoxypurine congeners of acyclovir, penciclovir and ganciclovir and some of their ester and ether derivatives have been reported (Krenitsky et al., 1984; Harnden et al., 1989; Vere Hodge et al., 1989; Winkler et al., 1990) to show improved absorption and to be converted to the antiviral agent in vivo, but acyclic acetal derivatives have not been evaluated previously for oral delivery of nucleoside analogues. In this publication, syntheses of novel acetal derivatives of BRL44385 and of its 2-aminopurine congener (BRL46720) are reported and their bioavailability and antiviral efficacy in mice are described.
Results

Chemistry
Acetal derivatives (6a-c) of 9-(3-hydroxypropoxy) guanine (BRL44385) were prepared by condensation of a monoacetal derivative (4a-c) of 1,3-dihydroxypropane with 2-[(bis-t-butoxycarbonyl)amino]-9-hydroxy-6-methoxypurine (3) under Mitsunobu conditions (Fig. 2) . The intermediate 9-alkoxy-2-[(bis-t-butoxycarbonylj-amino]-6-methoxypurines (5a-c) were obtained in 46-98% yield and were de-protected by treatment with sodium methoxide in methanol and then with 2-mercaptoethanol to afford the required 9-substituted guanines (6a-c) in 25-90% yield.
For preparation of acetal derivatives (1Oa-d) of 2-aminopurine two routes were used. The first (Fig. 3) involved reaction of an alkoxyamine (8b,d) with 4,6-dichloro-2,5-diformamidopyrimidine to afford a 4-chloro-6-alkoxyaminopyrimidine (9b,d) in a yield of approximately 50%. This was cyclized using diethoxymethyl acetate and the resultant 6-chloropurine, without purification, was hydrogenated and deprotected to give 9-substituted 2-aminopurines (10b,d) in 41% and 55% overall yield, respectively.
The second route (Fig.4) involved the intermediacy of 2-[(bis-t-butoxycarbonyl)amino]-6-chloro-9-hydroxypurine (12), which was prepared in three stages in 51% overall yield from 9-benzyloxy-6-chloro-2-formamidopurine (1) . was condensed with monoacetal derivatives (4a,c) of 1,3-dihydroxypropane under Mitsunobu conditions to afford .x BRL44385 OH BRL46720 H R = CH20(CHihOH, Acyclovir R = (CH2hCH(CH20Hh, Penciclovir R = CH20CH(CH20Hh, Ganciclovir Fig.1 . Acyclopurlnes, methoxy)propoxy derivative (6b) was better absorbed than BRL 44385, it was not totally converted to the antiviral agent and the concentrations of BRL44385 in the blood were similar to those seen after oral administration of BRL44385 itself. The (ethoxymethoxy)propoxy derivative (6a) was not as well absorbed as (6b) and provided lower concentrations of BRL 44385 in the blood and the (benzyloxymethoxy)propoxy derivative (6c) was not detectable at the administered dose levels. (Table 1) . No significant improvement in bioavailability of BRL 44385 was achieved with the 9-[3-(alkoxymethoxy)-propoxyjquanines (6a-c). Although the (isopropoxy-9-alkoxypurines (t3a,c) in 46% and 85% yield, respectively. Subsequent hydrogenolysis provided in 86% and 89% yield 2-[(bis-t-butoxy-carbonyl)aminol-9-alkoxypurines (14a,c), which were de-protected using sodium methoxide to give the 2-aminopurine derivatives (1Oa,c) in 89% and 60% yield, respectively, 5a-c However, with the exception of the (benzyloxymethoxy)propoxy derivative (tOC) which, like (6c), was not detected, the acetal derivatives of 2-amino-9-(3-hydroxypropoxy)purine (BRL46720) are of greater interest. The improved bioavailability of BRL44385 after oral administration of BRL46720 has been reported previously (Harnden et aI., 1989) . The (ethoxymethoxy)propoxy derivative (1Qa) was not as well absorbed as BRL46720, but provided a different BRL44385 blood profile, giving a much lower concentration at 15 min and a higher concentration at 60 min.
The (isopropoxymethoxy)propoxy (tOb) and (methoxymethoxy)propoxy (1Od) derivatives were both absorbed very well, but conversion to BRL44385 was much more efficient in the case of (10b). With (tOd) the major metabolite in the blood was 9-(methoxymethoxy)-propoxyguanine, and only a low concentration of BRL 46720 was seen indicating that for (1Od) oxidation at the 6-position of the purine moiety occurs more efficiently than cleavage of the acetal. This was not so after administration of (tOb), when the major metabolite was (Fig. 5 ). These studies demonstrate the novel and effective use of the isopropoxymethyl group as a pro-drug form of acyclonucleosides, and as a means to obtain improved oral absorption and delivery of an active antiviral drug. Studies are continuing on the evaluation of BRL 55792. Comparison of the efficacy of orally administered aRL 55792 (10b) and aRL 44385 against a cutaneous H8V-1 infection in the ear pinna of mice. Infection of the mouse ear pinna with HSV-1 results in a cutaneous infection which is usually self limiting and has a low lulose by oral gavage to female Balb/c mice weighing approximately 20g. Food was withheld for 18 h prior to the start of the experiment. Blood was collected by cardiac puncture using heparinized syringes 15, 60, and 180min after dosing. Equal volumes (O.2ml) from three mice were pooled at each time point and 0.6 ml of 16% trichloroacetic acid was added. After centrifugation, 0.5 ml of supernatant was added to 0.1 ml of saturated aqueous NaHC0 3 followed by the addition of 0.6ml of OAM NH 40Ac (pH 6.0) and the mixture analysed by HPLC (Nova-PAK C18, eluting with a linear gradient of 20mM potassium dihydrogen phosphate -80% methanol-water, 99-1 to 5-95% over 24min at 0.6ml mln". flow rate. The limit of detection for the compounds was 0.25119 rnr") b 9-Alkoxypurine concentrations detected in the blood 180 min after dosing were <211M. C For a plot of BRL 44385 concentration in the blood against time after dosing (up to 180 min):
area-under-the-curve after oral administration of test compound area-under-the-curve after intravenous administration of BRL44385 Na salt Female BALB/c mice were cutaneously infected in the right ear pinna with HSV-1 strain SC16 (5 x 10 5 p.f.u. per ear) as previously described (Boyd et a/., 1988) . Groups of 10 mice were treated with BRL44385 or BRL 55792, administered in 1% carboxymethyl cellulose plus 1% Tween 80 in water, orally twice daily for 5 days starting 1h after infection. The control animals received vehicle alone. The severity of the infection was assessed daily as follows: 0, no sign of infection; 1, erythema; 2, a few small isolated vesicles; 3, multiple isolated vesicles; 4, coalesced vesicles; 5, ulcerative lesion. Comparisons of treatments were carried out by analysis of variance of the area-under-the-Iesion-time curves.
Symbols: -0-, placebo ***; -+-, BRL443850.2 mmol kg-'; __-, BRL55792 0.2 mmol kg-'**;--o-, BRL55792 0.07mmol kg-' NS; ,BRL55792 0.02 mmol kg-'***.
Significance vs BRL44385 (0.2 mmol kg-'): **, P<0.01; ***, P<0.001; NS, not significant. mortality (Harbour et al., 1981) . Treatment with either oral BRL44385 (0.2 mmol kg-1) or BRL55792 (0.2 mmol kg-1 or 0.07 mmol kg-1) leads to a significant reduction in lesion severity (P<0.001) (Fig. 5 ). At an equal dose level (0.2 mmol kg-1) BRL55792 was significantly more effective than BRL44385 (P<0.01). In addition, BRL 55792 at 0.07 mmol kg-1 had comparable efficacy to 0.2 mmol kg-1 BRL 44385, indicating that the oral prodrug was at least three-fold more potent than the parent compound. These results demonstrate that the increased bioavailability of BRL44385 following oral administration of BRL55792 results in improved efficacy against a cutaneous H8V-1 infection in mice.
In a second study (data not shown), BRL55792 (0.07 mmol kg-1) was significantly more effective than ACV at 0.2 mmol kg-1 (P<0.05). The per cent reductions in lesion severity relative to placebo for BRL55792 (0.07 mmol kg-1) and ACV (0.2 mmol kg-1) were 70% and 52% respectively.
Materials and Experimental procedures: chemistry
Melting points were determined by using a Reichert Kofler apparatus and are uncorrected. 'H NMR spectra were recorded with a Varian EM-390 90-MHz or a JEOL GX-270 270-MHz spectrometer. Infra-red spectra were recorded with a Perkin-Elmer 580 spectrometer and ultraviolet spectra were recorded with a Uvikon 810 spectrometer. Mass spectra were recorded on a VG 70-70 instrument, and accurate masses were measured on a VG ZAB spectrometer. Microanalyses were performed on a Carlo-Erba Model 1106 analyser and, where only the symbols for the elements are recorded, were within ±0.4% of the calculated values. Upon thin-layer chromatography (TLC) of analytical samples using silica gel 60F 2s4, in each case only a single component was detected. Column chromatography was carried out using silica gel ICN 32-63 60A or Merck 7736 60H.
2-Amino-9-benzyloxy-6-methoxypurine (2)
A mixture of 9-benzyloxy-6-chloro-2-formamidopurine (1) (27 g, 98.2 mmol), sodium methoxide solution (2.3g Na in 600 ml MeOH, 100 mmol) was heated under reflux for 1.5 h. The cooled reaction mixture was neutralized with glacial acetic acid, the solvent was evaporated under reduced pressure and the residue was partitioned between chloroform-water. The organic layers were dried (MgS0 4), filtered, and evaporated under reduced pressure. The residue was purified via column chromatography on a silica gel, eluting with chloroformmethanol (99:1) to afford 2-amino-9-benzyloxy-6-methoxypurine (2) (14.5g 60%), m.p. 149-151°C: IR(KBr) 'Il max 3480, 3210,3190,2960 'Il max 3480, 3210,3190, ,1625 'Il max 3480, 3210,3190, ,1580 'Il max 3480, 3210,3190, ,1500 'Il max 3480, 3210,3190, ,1485 'Il max 3480, 3210,3190, ,1460 'Il max 3480, 3210,3190, ,1400 'Il max 3480, 3210,3190, ,1330 'Il max 3480, 3210,3190, , 1265 
3-(Alkoxymethoxy)propanols (4a-d)
A solution of the appropriate alkoxymethyl chloride (50mmol) in dry tetrahydrofuran (10ml) was added dropwise to stirred solution of 1, 3-propanediol (150mmol) and N, N-diisopropylethylamine (75mmol) in dry tetrahydrofuran (100ml) maintained at 0-5°C. The mixture was allowed to warm to room temperature and then stirred for 2 h. The solvent was evaporated and the residue purified via column chromatography on silica gel, eluting with dichloromethane: methanol (98:2) to afford to 3-(alkoxymethoxy) propanols (4a-d) as colourless oils. 
3-(Ethoxymethoxy) propanol (4a
9-[3-(Alkoxymethoxy)propoxyj-2-[(bis-t-butoxycarbonyl)-aminoj"6-methoxypurines (5a-c)
A mixture of 2-[(bis-t-butoxycarbony\)aminoj-9-hydroxy-6-methoxypurine (3) (2.0 g, 5.23 mmol), the appropriate 3-alkoxymethoxypropanol (4a-e) (5.75 mmo\) and triphenylphosphine (2.06 g, 7.87 mmol) in dry tetrahydrofuran (50ml) was cooled to 0-5°C and treated with a solution of diethyl azodicarboxylate (1.24 ml, 7.87 mmol) in dry tetrahydrofuran (10ml). The reaction mixture was stirred for 16h at room temperature and then evaporated under reduced pressure. The residue was purified via column cljf.omatography on silica gel, eluting with n-hexane-acetoneYlt3:1) to afford the 9-[3-(alkoxymethoxy)propoxyjpurines (5a-c). 
2-[(Bis-t-butoxycarbonyl)aminoj-9-[3-(ethoxymethoxy)propoxyj-6-methoxypurine (5a
2-[(Bis-t-(butoxycarbonyl)amino]-9-[3-(isopropoxymethoxy)propoxyj-6-methoxypurine (Sb
2-[(Bis-t-butoxycarbonyl)aminoj-9-(benzyloxymethoxy)propoxyj-6-methoxypurine (5c
9-[3-(Alkoxymethoxy)propoyjguanines (5a-c)
A solution of the appropriate 9-[3-(alkoxymethoxy)propoxyj-6-methoxypurine (5a-c) (1.4mmol) in sodium methoxide in methanol (0.5M, 25ml) was heated for 18h at reflux temperature. 2-Mercaptoethanol (1ml) was then added and heating was continued for a further 18h. The cooled reaction mixture was then neutralized with 0.5M aqueous hydrochloric acid and the solvent was evaporated under reduced pressure. The residue was purified via column chromatography on silica gel, eluting with chloroform: methanol (9:1) to afford the 9-(3-alkoxymethoxy)propoxyj guanine (6a-e). 
9-[3-(Ethoxymethoxy)propoxyjguanine (6a
9-[3-(lsopropoxymethoxy)propoxyjguanine (6b
9-[3-(Benzyloxymethoxy)propoxyjguanine (6c)
.
N-Alkoxyphthalimides (7b, d)
A solution of the appropriate 3-alkoxypropanol (4b, d) (36 mmol), N-hydroxyphthalimide (5.86g, 36 mmol) and triphenylphosphine (10.48g, 40mmol) in dry tetrahydrofuran (75ml) was cooled to 0-5°C and treated with diethyl azodicarboxylate (6.96g, 40mmol) in dry tetrahydrofuran (15m\) over 15 min. The reaction mixture was then stirred at room temperature for 18h. The solvent was evaporated under reduced pressure and the residue was dissolved in diethyl ether (100ml) and cooled to 0-5°C for 2h. The solid was removed by filtration and the filtrate was evaporated under reduced pressure. The residue was purified via column chromatography on silica gel, eluting with n-hexane: ethyl acetate (7:3) to afford the N- 
Alkoxyamines (Bb, d)
A solution of a N-alkoxyphthalimide (7b,d) (32mmol) in dry dichloromethane (70ml) at room temperature was treated with N-methylhydrazine (2.2g, 48mmol) and stirred for 2 h. The reaction mixture was filtered, the solvent evaporated under reduced pressure and the residue purified via column chromatography on silica gel, eluting with n-hexane:ethyl acetate (6:4) to afford the alkoxyamines (ab, d). 
3-(lsopropoxymethoxy)propoxyamine (8b)
3-(Methoxymethoxy)propoxyamine (8d)
6-[3-(Alkoxymethoxy)propoxy]amino-4-chloro-2,5-diformamidopyrimidines (9b, d)
A mixture of an alkoxyamine (Bb, d) (12.5mmOI), N, N-diisopropylelhylamine (3.24g, 25mmol) and 4,6-dichloro-2, B-diformamidopyrimidine (2.95g, 12.5mmol) in diglyme (50ml) was heated at 100°C for 3h. The reaction mixture was cooled, filtered and the solvent evaporated from the filtrate under reduced pressure. The residue was purified via column chromatography on silica gel, eluting with n-hexane:ethyl acetate (1:1) to afford the 6-[3-(alkoxymethoxy)propoxy]aminopyrimidines (9 b,d ). -2,S-diformamido-6-[3-(isopropoxymethoxy) propoxy]-arninopyrimidine (9b). Yield, 46%: m.p. 132-134°C (from ethyl acetate); IR (KBr) u m ax 3250, 2960 , 2920 , 2870 , 1705 , 1645 , 1590 , 1560 , 1495 , 1380 , 1335 1H NMR [(C0 3bSO] 0 1.08 (6H, d, J=6Hz, (CH 3hCH), 1.84 (2H, quintet, J=6.3Hz, CH 2CH2CH2), 3.58 (2H, t, J=6.3Hz, CH 20CH2CH2) 3.76 (1H, quintet, J=6Hz, (CH 3hCHO), 3.93 (2H, t, J=6.3Hz, CH 20N), 4.61 (2H, s, OCH 20), 8.14 (1H, s, NHCHO), 9.25 (1H, br. s -2,S-diformamido-6-[3-(methoxymethoxy) 3240 2920, 2880, 1705, 1640, 1590, 1565, 1495, 1465, 1410 and 1380cm- -9-[3-(alkoxymethoxy) propoxy]purines (10b, d) A mixture of a 6-[3-(alkoxymethoxy)propoxy]amino-4-chloro-2,5-diformamidopyrimidine (9 b.d) (5 mmol) and diethoxymethyl acetate (1Oml)was heated at 120°C for 1h. The solution was evaporated under reduced pressure, and the residue was dissolved in methanol (15ml) and concentrated aqueous ammonia (1.5ml). After 1h at 20°C the solvent was removed under reduced pressure to afford purine derivatives which, without further purification, were dissolved in methanol (30ml). To this solution triethylamine (3.5ml, 25m mol) and 10% palladium on charcoal (180mg) were added and the mixture was stirred under an atmosphere of hydrogen at 20°C for 4h. The suspension was filtered, the catalyst was washed with chloroform and the combined filtrates were evaporated under reduced pressure. The residue was then dissolved in dichloromethane (50ml) and the solution was washed with saturated brine, dried (magnesium SUlphate) and evaporated under reduced pressure. The residue was dissolved in 0.5M sodium methoxide in methanol (20ml) and heated under reflux for 1h. The solution was cooled, neutralized using Amberlite IR 120 (H) resin and evaporated under reduced pressure. The residue was purified via column chromatography on silica gel, eluting with chloroform: methanol (20:1) to afford the 2-aminopurine derivatives 10 b, d. -9-[3-(isopropoxymethoxy) -9-[3-(methoxymethoxy) propoxy]purine (10d). Yield, 55%, m.p. 80-81°C (from acetone-n-hexane); UV (MeOH) A m ax 223 (1'.26,375),245 (1'.5020) and 310 (I'. 7320)nm; IR (KBr) u m ax3320, 3180, 3080,2940 , 2880 ,1645 ,1610 ,1580 ,1505 , 1465 1H NMR [(C0 3hSO] -9-benzyloxy-6-chloropurine (11) A solution of 9-benzyloxy-6-chloro-2-formamidopurine (1) (10g, 33mmol) in sodium ethoxide (0.38M, 50rl11)/ethanol (250ml) was heated to reflux for 1.5h. The cooled reaction mixture was neutralized with acetic acid and the solvent was evaporated under reduced pressure. The residue was purified via column chromatography on silica gel, eluting with chloroformmethanol (98:2) to afford the 2-aminopurine (11) (5.4g, 60%): IR (KBr) '\lmax 3397, 3312, 3205, 1635, 1558, 1505, 1468, 1405,1365,1320,1247, and 
4-Chloro
2-Amino
2-Arnino
2-Amino
2-[(Bis+butoxycarbonyl)aminoj-6-chloro-9-hydroxypurine (12)
A mixture of z-amino-s-benzyloxy-a-ctnoropunne (11) (6.73g, 24.4mmol), di-t-butyldicarbonate (7.9$,9, 36.4mmol) and 4-dimethylaminopyridine (0.6g, 4.9mm81) in tetrahydrofuran (100ml) was stirred at room temperature for 6h. The reaction was then filtered through a silica gel pad and the pad was washed with tetrahydrofuran (3 x50ml). The combined filtrates were evaporated under reduced pressure and the residue was purified by chromatography on a silica gel column, eluting with hexane-acetone (3:1) to afford 9-benzyloxy-2-[(bis+butoxy-carbonyl)aminoj-6-chloropurine (7.5g), which was dissolved in tetrahydrofuran (150ml). Five per cent palladium on charcoal (750mg) was then added and the mixture was stirred under an atmosphere of hydrogen at 20°C for 4h. The suspension was filtered, the catalyst was washed with chloroform and the combined filtrates were evaporated under reduced pressure. The residue was purified via column chromatography on silica gel, eluting with chloroform-methanol (95:5) to afford the s-hydroxypurine (12) (5.2g, 83%): IR (KBr) '\lmax 3434, 3100, 2980 , 2934 ,1778 ,1743 ,1706 ,1603 ,1566 ,1477 ,1393 ,1370 , 1294 1H NMR [(CD 3hSOj 8 1.41 (18H, s, [(CH 3hCOb), 8.93 (1H, s, H-8), 12.80 (1H, br.s, OH) ; ElMS m/z 386 (MW). Anal (C1sH2oNsOsCI) C, H, N.
9-[3-Alkoxymethoxy)propoxyj-2-[(bis-tbutoxycarbonyl)aminoj-6-chloropurines (13a,c)
A mixture of 2-[(bis-t-butoxycarbonyl)aminoj-6-chloro-9-hydroxypurine (12) (2.4 g, 7.46 mrnol), the appropriate 3-(alkoxymethoxy)propanol (4a,c) (7.46 mmol) and triphenylphosphine (2.62 g, 10 mmol) in dry tetrahydrofuran (25 ml) was cooled to 0-5°C and treated with a solution of diethyl azodicarboxylate (1.58 ml, 10 mmol) in dry tetrahydrofuran (5ml). The reaction mixture was stirred for 16h at room temperature and then evaporated under reduced pressure. The residue was purified via column chromatography on silica gel, eluting with chloroform-methanol (98:2) followed by further chromatography on silica gel eluting with acetone-hexane (10:90) to afford the 9-[3-alkoxymethoxy)propoxyj-2-[(bis-tbutoxycarbonyl)aminoj-6-chloropurines (13a, c). . Yield, 46%: gum; IR (film) '\lmax 3100, 2980,2930,2880,1795,1760,1600,1560,1475,1425,1390, 1370,1340,1280 and 1250 and the residue was purified via column chromatography on silica gel, eluting with ethyl acetate:n-hexane (6:4) to afford the 2-amino-9-[3-(alkoxymethoxy)propoxy]purines 10 ave.
